Clinical Trial Insurance: What It Covers, What It Costs, and Where the Gaps Are

Quick Answer

Clinical trial insurance is a specialized liability policy that protects sponsors, biotech firms, and research sites against claims tied to participant injury, regulatory investigations, and trial-related legal costs. Pricing ranges from a few thousand dollars for a small single-site study to a substantial annual premium for large, multi-country, later-phase trials, and cost depends heavily on trial phase, participant count, and product risk.

TL;DR:

Clinical trial insurance protects life science and biotech companies from the legal and financial fallout of participant injury, regulatory action, and trial cancellation.
Coverage is priced on risk factors, not a flat rate: trial phase, participant count, product type, and geographic scope all move the premium.
Most sponsor liability policies do not automatically pay a participant’s full medical bills the way health insurance does, which is a coverage gap founders frequently misunderstand.
The Coyle Group structures this coverage around the specific protocol and regulatory exposure of the trial, not a generic template.

If you are running or funding a clinical trial and your program has not been independently reviewed, the gap between what you think is covered and what is actually covered is usually where the exposure lives. Founders in life sciences and biotech tell us the same thing in almost every first conversation: they assumed general liability or a standard business owner’s policy would extend to trial participants, only to learn during underwriting (or worse, during a claim) that it does not. A single serious adverse event during a trial can trigger legal defense costs, a regulatory inquiry, and a participant injury claim all at once, and a policy that was never built for that combination leaves real gaps exposed at the worst possible moment. The Coyle Group is a commercial insurance agency that handles the complex, high-value risks other agencies don’t know how to structure, where the details in the policy are the difference between a paid claim and a denied one.

Life science and biotech companies often carry insurance built for general business risk, not the specific liability of running a clinical trial.

We build the policy around your actual trial protocol and regulatory exposure, not a generic template, so the coverage matches the risk you are really carrying.

Gordon B. Coyle has spent over 40 years working with startups and early-stage life science firms through 7, 8, and 9-figure growth, building coverage around the actual protocol, not a generic template.

Book a call to have your current program reviewed before your next trial phase begins.

Book a call

What Is Clinical Trial Insurance?

Clinical trial insurance is a specialized liability policy protecting companies that sponsor or conduct clinical trials, responding when a claim arises from participant injury, adverse reaction, or regulatory action. A frequently overlooked nuance: most policies split responsibility into two buckets, protecting the sponsor from being sued, and compensating the participant, and those are not the same coverage.

This type of coverage exists because testing new drugs, biologics, and medical devices on human participants carries risk that a standard commercial general liability policy was never designed to price. It provides financial protection if something goes wrong during the trial process, covering legal defense, settlements, and in many cases the direct compensation owed to an injured participant.

According to guidance compiled by CASRAI’s clinical trial indemnity and insurance framework, international standards under ICH E6 require sponsors to provide insurance or indemnify the investigator and institution against claims arising from the trial, except for claims tied to malpractice or negligence, which is exactly the kind of carve-out that trips up first-time sponsors.

Not sure how clinical trial insurance actually responds to a real claim? Watch Gordon break down what it covers and where standard business policies leave trial sponsors exposed.

Legal-Liability vs. No-Fault Coverage

Coverage in this space is generally built on one of two bases, and knowing which one your program uses matters more than most sponsors realize:

Legal-liability coverage requires the participant (or their attorney) to prove negligence before the policy pays a claim.
No-fault coverage pays out when an injury can reasonably be attributed to the investigational product or a required trial procedure, regardless of whether anyone was negligent.

No-fault coverage is generally considered more participant-friendly and is often required or expected in trials conducted outside the United States.

Why Do Life Science and Biotech Companies Need Clinical Trial Insurance?

Life science and biotech companies need this coverage because a single participant injury claim, regulatory investigation, or trial cancellation can be financially devastating for a pre-revenue company. The related nuance: consequences reach beyond the claim itself into investor confidence and operational continuity, since testing new treatments on human participants carries risk that funding rounds watch closely.

Bringing new medical treatments to market requires testing on human participants, and for startups and early-stage companies in this sector, one uninsured claim can derail years of work and funding. In our experience reviewing these programs, a single trial-related claim can run well into six or seven figures once legal defense, regulatory response, and any settlement are combined, and that is before accounting for the operational disruption of a paused or cancelled trial. Insurance built for this specific exposure exists to prevent one incident from becoming an existential event for the company.

There are four main reasons this coverage is treated as a baseline requirement rather than a nice-to-have in this sector.

Regulatory Compliance

Clinical trials must adhere to strict regulatory standards, and non-compliance can lead to significant legal exposure. The FDA’s guidance for institutional review boards (IRBs), the independent ethics committees that approve and monitor human research, confirms that whether compensation and medical treatment are offered to injured participants is generally determined by institutional policy rather than a single federal mandate, which means the sponsor’s own program, not a government backstop, is what actually protects the participant and the company. A properly structured policy helps cover legal costs associated with regulatory investigations and compliance failures when the trial’s conduct is questioned.

Protecting Participants

Participants in clinical trials are vital to the development of new treatments, and insurance ensures that if a participant suffers harm, they are compensated in a way that also protects the company from the direct financial burden of that claim. Insurance access issues are not a hypothetical concern either: a study published in Clinical Cancer Research found that 13.6% of insured patients were denied enrollment in a therapeutic cancer trial specifically because of coverage gaps, with an average clearance delay of about six business days once a case was flagged (see the Johns Hopkins analysis of insurance and clinical trial access). A well-structured program removes that friction for both the participant and the sponsor.

Investor Confidence

Investors want to know that their capital is protected, and having this coverage in place shows that a company takes risk management seriously, which makes it a more attractive investment. This is closely tied to how a company structures its broader directors and officers insurance program, since board members and executives can be personally named in a lawsuit stemming from a mishandled trial, and investors increasingly expect both coverages to be addressed together before a funding round closes.

Operational Continuity

In the event of a claim, insurance helps cover the cost without crippling the company’s finances, allowing operations to continue and progress on the underlying research program to keep moving. Without that buffer, a single claim can force a company to pause enrollment, delay a funding milestone, or, in the worst case, shut down the trial entirely.

What Does Clinical Trial Insurance Cover?

Clinical trial insurance covers four primary exposure areas, participant injury, legal defense costs, regulatory actions, and trial cancellation, and the related nuance is that not every policy covers all four by default, so the specific trigger language matters as much as the limit. Reviewing exactly which of these four are included, and under what conditions, is the single most important step before enrollment begins.

Coverage Area	What It Protects
Participant Injury	Medical expenses and compensation for participants who suffer injury or harm during the trial.
Legal Defense Costs	Legal fees and expenses if the company is sued because of the trial.
Regulatory Actions	Costs associated with responding to regulatory investigations or enforcement actions.
Trial Cancellation	Some policies extend coverage if a trial is cancelled due to adverse events or regulatory issues.

To make this concrete, here are two real-world claim patterns that come up repeatedly in this space:

Claim Example One

A biotech firm is conducting a trial for a new drug, and a participant suffers a serious adverse reaction. The participant sues the company for medical costs and damages, and the policy covers the legal fees and the settlement amount, saving the company from a significant financial hit.

Claim Example Two

A life science startup faces a regulatory investigation after a trial is found to have procedural errors. The policy covers the legal costs and fines associated with the investigation, keeping the company solvent while it responds.

What 40+ Years in This Business Teaches You

“Bottom line is that almost all insurance programs we review contain at least one fatal mistake.” (Gordon Coyle)

That is exactly the pattern we see when we audit a life science company’s program for the first time: the general liability and errors and omissions policies look complete on paper, but the clinical trial exposure was never actually underwritten into either one.

The Coverage Gap Nobody Explains Upfront

Here is the nuance that catches almost every first-time sponsor off guard: a sponsor’s liability policy is not the same as health insurance for the participant. It protects the company from being sued, but it typically does not automatically pay a participant’s full medical bills the way health coverage would. Many policies cap the built-in medical expense benefit at a relatively modest sublimit, which can fall far short of the actual cost of treating a serious adverse event. Sponsors who assume “we have insurance” means “the participant’s medical bills are handled” are often wrong, and that gap should be addressed explicitly in the policy, not discovered after a claim.

What Industries and Companies Need Clinical Trial Insurance?

This coverage is most relevant to any organization that sponsors, funds, or directly conducts human trials, and the related nuance is that the requirement follows the trial itself, not just the company’s size or funding stage. A pre-revenue startup running its first Phase 1 study faces the same participant-injury exposure as a funded company running a Phase 3 program, just at a different scale.

Companies and organizations that typically need this coverage include:

Biotech and pharmaceutical startups developing new drugs, biologics, or gene therapies for human testing.
Medical device manufacturers testing implantable, surgical, or diagnostic devices on human subjects.
Contract research organizations (CROs) managing trials on behalf of sponsors.
Hospitals, universities, and academic medical centers hosting trials as the physical research site.
Digital health and diagnostics companies running clinical validation studies for software-based or wearable medical technology.
Later-stage pharmaceutical companies running multi-country Phase 3 and Phase 4 programs with larger participant pools.

Insurance carriers active in this space, such as Chubb’s clinical trials liability program, specifically underwrite biotechnology firms, pharmaceutical manufacturers, medical device companies, hospitals, universities, and research institutes, confirming just how broad this need actually is.

Biotech Company Insurance Explained

Because most life science companies in this position are also building out their broader risk program at the same time, it is worth reviewing how this fits alongside insurance for technology companies if the company’s platform includes any software or data component, and alongside product recall insurance once a product moves toward commercialization.

When You May Not Need a Standalone Policy Yet

Not every life science company needs this coverage at every stage. A company still in preclinical or animal research, with no human participants enrolled, does not yet carry the exposure this policy is built for. Once a product clears the trial process and reaches the market, the relevant exposure generally shifts to product liability rather than trial participant injury. And a site running a trial entirely under a sponsor’s or CRO’s master indemnification program, with its own coverage confirmed in writing, may not need a separate standalone policy, though that assumption is worth verifying rather than taking on faith.

What Are the Key Benefits of Clinical Trial Insurance?

The key benefit of this coverage is that it converts an unpredictable, potentially company-ending liability into a fixed, budgetable expense, and the related nuance is that the benefit compounds across every stakeholder in the trial, not just the sponsor. Framed in terms of what a policyholder actually gains:

Risk transfer. A single adverse event no longer has to come out of operating cash or a funding round.
Regulatory standing. Demonstrating financial responsibility for participant harm is often expected by IRBs and, in international trials, required by local regulation.
Investor and partner confidence. A properly structured program signals operational maturity during diligence.
Participant trust. Clear, funded compensation terms make enrollment and informed consent conversations more straightforward.
Continuity of the research program. The company can keep the trial moving instead of pausing to manage a claim internally.

How Much Does Clinical Trial Insurance Cost?

The cost of clinical trial insurance is not a single number: the same coverage limit can price very differently depending on four underwriting factors, so read any quote alongside the specific risk profile it was built for. Cost is understandably the first thing on a life science leader’s mind, and the factors that drive pricing are consistent across the market.

Factor One: Potential liabilities and risk profile

Clinical trials carry significant financial risk from participant injuries, adverse events, and legal claims. The higher the perceived risk profile of the trial, the higher the premium, to account for the increased liability the insurer is taking on.

Factor Two: Trial phase

Later-phase trials, specifically Phase 3 and Phase 4, generally involve more participants over longer durations, increasing exposure compared to earlier-phase studies. That higher exposure typically translates into higher premiums for later-phase trials.

Factor Three: Number of participants and product type

More participants means a higher probability of an adverse event occurring, which increases the liability that needs to be insured. Trials involving higher-risk treatments, products, or procedures may also require higher coverage limits due to the increased chance of complications.

Factor Four: Geographic scope

Trials conducted across multiple countries or regions, each with its own regulations and liability standards, require a more comprehensive global coverage program, which affects the premium.

Underwriters weigh all four factors together to build a risk profile and price the policy accordingly, which is why coverage is not cheap given the stakes involved, but it is also not one-size-fits-all. A small, single-site oncology study and a large multinational Phase 3 program will not land anywhere near the same premium, which is exactly why a generic quote without underwriting detail should be treated with caution.

For a sense of scale, the specialized trial liability premium is only part of what a trial sponsor typically budgets for. The Hartford’s published cost data puts the surrounding commercial program many sponsors also carry at roughly $810 a year for standalone general liability, $1,687 a year for a business owner’s policy, and $1,032 a year for workers’ compensation, all separate from the dedicated clinical trial liability premium itself, which prices individually against the four factors above rather than off a published rate.

This is also a narrower market than most commercial lines. Not every carrier writes clinical trial liability, and the handful that do, including Chubb and The Hartford, underwrite it as a specialty product with its own application and documentation requirements. A generalist agency that only occasionally touches this coverage may not have standing relationships with the carriers that actually write it, which shows up as slower quoting, thinner limits offered, or coverage terms that were never actually negotiated.

What Policy Structure Details Actually Matter?

Two policies with identical coverage areas and limits can still respond very differently to the same claim, and the related nuance is that these structural details are usually the last thing a sponsor asks about, not the first. Before binding a policy, confirm the following:

Claims-made vs. occurrence trigger. The Hartford explains that a claims-made policy only responds if the claim is filed during the policy period (or an extended reporting period) and the incident happened on or after the policy’s retroactive date, while an occurrence policy responds to any incident during the policy period regardless of when the claim is later filed. Trial-related injuries can surface years after a study closes, which makes this distinction directly relevant to clinical trial insurance.
Retroactive date. On a claims-made policy, an incident that occurred before this date is not covered, so the retroactive date needs to reach back to cover the trial’s actual enrollment period, not just the date the current policy was purchased.
Tail, or extended reporting period, coverage. The Hartford notes this typically runs 30 to 60 days after a policy is cancelled or not renewed, which is rarely enough time for a trial-related injury to surface and be reported. A longer negotiated tail matters more here than in most commercial liability lines.
Named insured structure. The sponsor, the CRO managing the trial, the individual investigators, and the host institution are often four different legal entities, and a policy that only names the sponsor can leave the others exposed or force them to carry duplicate coverage.
Contract-driven limit requirements. A CRO, academic medical center, or enterprise partner will frequently specify minimum limits in its own contract before it will host or manage a trial, and those figures should be checked against the policy before a site agreement is signed, not after.

What Are the Downsides and Coverage Gaps to Watch For in Clinical Trial Insurance?

The biggest downside here is not the premium, it is the exclusions, and the related nuance is that most of those exclusions only become visible once you compare the policy language against the actual trial protocol, not the marketing description of the coverage. Common gaps and pitfalls include:

Negligence and malpractice carve-outs. Standard indemnification language typically excludes claims arising from the institution’s own negligence or willful misconduct, which shifts that specific risk back onto the site or investigator.
Disease progression exclusions. Coverage generally does not extend to a participant’s underlying disease progressing on its own, separate from the trial intervention.
Modest medical expense sublimits. The built-in medical benefit for a participant’s treatment is often capped well below what a serious adverse event can actually cost, leaving a gap between what the policy pays and what treatment requires.
Multinational compliance gaps. A single domestic policy will not automatically satisfy every country’s local insurance or indemnification requirement, and a fragmented program can leave a trial site technically non-compliant.
Assuming general liability already covers it. This is the single most common mistake we see: treating clinical trial exposure as something a standard business owner’s policy or umbrella already absorbs, when it typically has not been underwritten for that risk at all. Reviewing how an umbrella and excess liability program actually responds to a trial-related claim, rather than assuming it does, is worth doing before you need it.

5 Insurance Mistakes That Can Destroy Your Startup

How Do You Buy Clinical Trial Insurance the Right Way the First Time?

You buy clinical trial insurance correctly by matching the policy to the trial’s actual structure before you ever enroll a participant, and the related nuance is that most of the mistakes on this list are made once, early, and then carried forward unnoticed through every renewal after that. For a company buying this coverage for the first time, the process looks like this:

Get coverage in force before enrollment, not after. The policy needs to be active before the first participant is exposed to the investigational product or procedure, not queued up once the trial is already underway.
Coordinate master and local policies before a multinational trial starts. If the trial runs in more than one country, confirm each jurisdiction’s insurance or indemnification requirement is met before that site opens enrollment, not after a local regulator asks for proof.
Match limits to what your contracts actually require. Pull the insurance requirements out of every CRO agreement, site contract, and institutional agreement tied to the trial, and size the policy to the highest of those, not to a generic industry average.
Confirm the trigger and the tail before you bind. Ask directly whether the policy is claims-made or occurrence, what the retroactive date is, and how long the extended reporting period runs if the policy is ever cancelled or not renewed.
Have someone read the exclusions against the actual protocol before signing. A generic coverage summary is not the same as confirming the policy responds to this specific trial’s product type, phase, and participant population.

How Do You Know If Your Clinical Trial Insurance Program Has Gaps?

This is a different question from the one above: buying it right is about setup, this is about auditing what is already in place. You know an existing program has a gap if nobody can tell you, in plain language, exactly what happens the moment a participant is injured, which is what most policy reviews are actually built around. Before your next trial phase begins, walk through these questions with whoever built your current program:

Confirm whether the policy pays on a legal-liability basis, a no-fault basis, or both, since that changes what your participants can actually claim.
Check the medical expense sublimit for an injured participant against the realistic cost of treating a serious adverse event.
Verify whether coverage extends to every country where the trial is running, not only the sponsor’s home jurisdiction.
Make sure your directors and officers program accounts for clinical trial litigation as a named exposure for your board.
Have someone read the exclusions against your specific protocol, rather than relying on a generic policy summary.

Why The Coyle Group Is the Right Partner for Clinical Trial Insurance

Gordon B. Coyle, CPCU, ARM, AMIM, PWCA, has spent more than 40 years working with business owners of every size, building coverage for life science and biotech founders around the actual protocol, not a generic template. The related nuance: a policy that looks complete on paper is not the same as a policy that pays when a real claim comes in.

The Coyle Group will leave no stone unturned to find the right combination of price and coverage for a program this specialized.

D&O Insurance for Tech Startups 2022

If your company is preparing for a trial, expanding into a later phase, or simply has not had its current program reviewed against its actual clinical trial exposure, that review is the right next step, not another generic quote.

Ready to close the gap in your clinical trial insurance program?

Book a Call with The Coyle Group

Related coverage to review alongside this program: management liability insurance for the executives overseeing the trial, cyber insurance and data breach insurance for the participant health data your trial collects, and what is professional liability or E&O insurance for the research and advisory services your team provides.

Quick Answers Before You Buy

What it is: A specialized liability policy covering participant injury, legal defense, and regulatory action tied to a clinical trial, built on either a legal-liability or no-fault basis.
Who needs it: Biotech and pharmaceutical startups, medical device manufacturers, CROs, hospitals and universities hosting trials, and later-stage sponsors running multi-country programs.
Who may not need it yet: Preclinical-only companies with no human participants enrolled, post-market products now facing product liability instead, and sites fully covered under a sponsor’s or CRO’s verified master program.
What it typically excludes: The institution’s own negligence or willful misconduct, disease progression unrelated to the trial, and medical expenses above the policy’s built-in sublimit.
What drives cost: Risk profile, trial phase, participant count and product type, and geographic scope, priced individually rather than off a published rate.
Structural details that matter: Claims-made versus occurrence trigger, the retroactive date, tail coverage length, and whether every named insured (sponsor, CRO, investigators, institution) is actually on the policy.
Why a specialist broker matters: This is a narrow specialty market carried by a small number of carriers, and a generalist agency without standing carrier relationships in this space typically means slower quoting and thinner negotiated terms.

Frequently Asked Questions

No. Clinical trial insurance covers the trial itself, meaning injury to a participant during testing, while product liability insurance applies after a product reaches the market and causes harm to a consumer or patient.

Only if the policy is structured to. A domestic policy will not automatically satisfy the insurance or indemnification requirements of every country where a trial runs, so multinational programs typically need coordinated master and local policies.

Typically the sponsor, since international guidance under ICH E6 places the obligation to insure or indemnify the investigator and institution on the trial sponsor.

Generally no. Standard commercial general liability was not built to price this exposure, which is exactly why a dedicated policy exists.

Before enrollment begins on the first trial, not after. Coverage needs to be in force before the first participant is exposed to the investigational product or procedure.

Some clinical trial insurance policies include coverage for costs tied to trial cancellation caused by adverse events or regulatory action, though this varies by policy and should be confirmed before the trial starts.

About the Author

This article was written by the CEO of The Coyle Group, Gordon B. Coyle, CPCU, ARM, AMIM, PWCA, who has over 40 years of experience working with business owners of all sizes and industries across the US, solving their insurance challenges.